Evidence map›Paper›PMID 32566038›Full record

ArticleDisease markers2020

Clinical Significance and Prognostic Value of miR-28-5p in Colon Cancer.

Ji-Lin Li, Ke-Zhi Li, Ming-Zhi Xie, Yan-Ping Tang, Yin-Lin Tang, Bangli Hu

Abstract read
In one paragraph

Article in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ji-Lin LiDepartment of Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Ke-Zhi LiDepartment of Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Ming-Zhi XieDepartment of Chemotherapy, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yan-Ping TangDepartment of Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yin-Lin TangClinical Laboratory, Maternal and Child Health Hospital of Guangxi, 530003 Nanning, Guangxi, China.
Bangli HuDepartment of Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China.ORCID https://orcid.org/0000-0002-4401-0601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe association of miR-28-5p with colon cancer remains to be elucidated. This study aimed to determine the clinical significance and prognostic value of miR-28-5p in colon cancer.

methodsWe retrospectively analyzed the data of miR-28-5p in colon adenocarcinoma data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), and the data was divided into cancer group and normal group, respectively. Forty colon cancer tissues and adjacent normal tissues were collected and tested by qRT-PCR methods. The difference of the miR-28-5p expression between colon cancer and normal tissues was compared. The clinical significance of miR-28-5p in colon cancer and the association with the survival were determined. The predictive value of miR-28-5p in clinical features was determined using receiver operating characteristic curve. The target genes of miR-28-5p were identified, and the functional of target genes was performed using bioinformatics analysis.

results: The expression of miR-28-5p was increased in colon cancer tissues compared with normal controls (

conclusions: This study demonstrated that miR-28-5p was increased in colon cancer and can be an independent indicator for the overall survival in patients with colon cancer.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorColonic NeoplasmsFemaleHumansMaleMicroRNAsMiddle AgedBiomarkers, TumorMicroRNAsMIRN28 microRNA, human

Identifiers

PMID32566038
PMCPMC7256711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.